Systemic antibiotics for toxoplasmic retinochoroiditis. Systematic literature review
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Objective: The main objective of this systematic review is to evaluate safety and efficacy of systemic antibiotics in active toxoplasmic retinochoroiditis.
Methods: An important search was conducted which included randomized or quasi-randomized controlled clinical trials. Studies carried out in immunocompromised patients were excluded. Studies of patients treated for acute retinochoroiditis or patients with inactive retinochoroidal scars and a history of two or more recurrent episodes of active disease were included. Well-known antibiotic regimens (trimethoprim/sulfamethoxazole, pyrimethamine/sulfadiazine, pyrimethamine/azithromycin), which have been widely used against Toxoplasma gondii, were included.
Results: The primary outcomes for this review were visual acuity and recurrences, defined as a new focus of inflammation next to a preexisting scar. Secondary outcomes were adverse effects, reduction of retinochoroidal lesion size and duration, severity and frequency of signs and symptoms due to intraocular inflammation.
Conclusions: There is still a lack of evidence to support the antibiotic and optimal dosage for the treatment of toxoplasmic retinochoroiditis, as well as the best prophylactic treatment for recurrences.
Article Details
References
Muccioli C, Silveira C, Belfort R. Ocular toxoplasmosis. Contemp Ophthalmol. 2007;6(10):1-8.
Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):34-40.
Bowie WR, King AS, Werker DH, Isaac-Renton JL, Eng SB, Marion SA. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet. 1997;350(9072):173-7.
Bahia-Oliveiria LM, Jones JL, Azevedo-Silva J, Alves CC, Orefice F, Addiss DG. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003;9(1):55-62.
Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with polymerase-chain-reaction test on amniotic fluid. N Engl J Med. 1994;331(11):695-9.
Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829-33.
Koo L, Young LH. Management of ocular toxoplasmosis. Int Ophthalmol Clin. 2006; 46(2):183-93.
Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980; 66(5):767-74.
Jenum PA, Stray-Pedersen B, Melby KK, Kapperud G, Whitelaw A, Eskild A, et al. Incidence of Toxoplasma gondii infection in 39 940 pregnant women in Norway and pregnancy outcome for infected women. J Clin Microbiol.1998; 36(10):2900-6.
Montoya JG, Remington JS. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis. 1996;23(2):277-282.
Ongkosuwito JV, Bosch-Driessen EH, Kijlstra A, Rothova A. Serologic evaluation of patients with primary and recurrent ocular toxoplasmosis for evidence of infection. Am J Ophthalmol. 1999;128(4):407-12.
Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):102-14.
Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology. 2003; 110(5):926-32.
Holland GN. Ocular toxoplasmosis: new directions for clinical investigation. Ocul Immunol Inflamm 2000;8(1):1-7.
Fardeau C, Romand S, Rao NA, Cassoux N, Bettembourg O, Thulliez P, et al. Diagnosis of Toxoplasmic Retinochoroiditis with Atypical Clinical Features. Am J Ophthalmol. 2002;134(2):196-203.
Rothova A. Ocular manifestations of toxoplasmosis. Curr Opin Ophthalmol. 2003;14(6):384-388.
Soheilian M, Sadoughi MM, Ghajarnia M, Dehghan NH, Yazdani S, Behboudi H, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112(11):1876-1882.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzshe PC, Loannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta – analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):1-30.
Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan H, Shahghadami R, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine and prednisolona in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134-41.
Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Opthalmol. 2004;137(1):1-17.
Silveira C, Belfort R Jr, Muccioli C, Holland GN, Victoria CG, Horta GL, et al. The Effect of LongIntermittent Trimethoprim/Sulfamethoxazole Treatment on Recurrences of Toxoplasmic Retinochoroiditis. Am J Ophthalmol.2002; 134(1):41-46.
Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of desease. Am J Opthalmol. 2003;136(6):973-88.
Gilbert RE, See SE, Jones LV, Stanford MS. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Syst Rev. 2002; (1):CD002218.